WallStSmart

IDEXX Laboratories Inc (IDXX)vsSotera Health Co (SHC)

VS

Smart Verdict

WallStSmart Research — data-driven comparison

IDEXX Laboratories Inc generates 270% more annual revenue ($4.30B vs $1.16B). IDXX leads profitability with a 24.6% profit margin vs 6.7%. SHC appears more attractively valued with a PEG of 1.68. SHC earns a higher WallStSmart Score of 62/100 (C+).

IDXX

Buy

61

out of 100

Grade: C+

Growth: 6.7Profit: 9.5Value: 4.7Quality: 5.0
Piotroski: 5/9

SHC

Buy

62

out of 100

Grade: C+

Growth: 4.7Profit: 7.5Value: 4.7Quality: 5.8
Piotroski: 6/9
IV

Intrinsic Value Comparison

Multi-model valuation · Graham Formula

IDXXSignificantly Overvalued (-40.2%)

Margin of Safety

-40.2%

Fair Value

$462.85

Current Price

$575.72

$112.87 premium

UndervaluedFair: $462.85Overvalued
SHCSignificantly Overvalued (-37.4%)

Margin of Safety

-37.4%

Fair Value

$12.64

Current Price

$13.70

$1.06 premium

UndervaluedFair: $12.64Overvalued

Key Strengths & Concerns

Side-by-side fundamental analysis

Key Strengths

IDXX3 strengths · Avg: 9.0/10
Return on EquityProfitability
66.2%10/10

Every $100 of equity generates 66 in profit

Profit MarginProfitability
24.6%9/10

Keeps 25 of every $100 in revenue as profit

Operating MarginProfitability
29.8%8/10

Strong operational efficiency at 29.8%

SHC1 strengths · Avg: 10.0/10
Operating MarginProfitability
35.7%10/10

Strong operational efficiency at 35.7%

Areas to Watch

IDXX3 concerns · Avg: 2.0/10
PEG RatioValuation
3.972/10

Expensive relative to growth rate

P/E RatioValuation
43.7x2/10

Premium valuation, high expectations priced in

Price/BookValuation
28.6x2/10

Trading at 28.6x book value

SHC4 concerns · Avg: 3.8/10
PEG RatioValuation
1.684/10

Expensive relative to growth rate

Revenue GrowthGrowth
4.6%4/10

4.6% revenue growth

EPS GrowthGrowth
1.8%4/10

1.8% earnings growth

Profit MarginProfitability
6.7%3/10

6.7% margin — thin

Comparative Analysis Report

WallStSmart Research

Bull Case : IDXX

The strongest argument for IDXX centers on Return on Equity, Profit Margin, Operating Margin. Profitability is solid with margins at 24.6% and operating margin at 29.8%. Revenue growth of 14.3% demonstrates continued momentum.

Bull Case : SHC

The strongest argument for SHC centers on Operating Margin.

Bear Case : IDXX

The primary concerns for IDXX are PEG Ratio, P/E Ratio, Price/Book. A P/E of 43.7x leaves little room for execution misses.

Bear Case : SHC

The primary concerns for SHC are PEG Ratio, Revenue Growth, EPS Growth. A P/E of 51.2x leaves little room for execution misses. Debt-to-equity of 4.14 is elevated, increasing financial risk.

Key Dynamics to Monitor

IDXX profiles as a mature stock while SHC is a value play — different risk/reward profiles.

SHC carries more volatility with a beta of 1.88 — expect wider price swings.

IDXX is growing revenue faster at 14.3% — sustainability is the question.

IDXX generates stronger free cash flow (323M), providing more financial flexibility.

Bottom Line

SHC scores higher overall (62/100 vs 61/100). Both earn "Buy" and "Buy" ratings respectively — the choice depends on your investment horizon and risk tolerance.

This analysis is generated from publicly available financial data. Not financial advice.

IDEXX Laboratories Inc

HEALTHCARE · DIAGNOSTICS & RESEARCH · USA

IDEXX Laboratories, Inc. is an American multinational corporation engaged in the development, manufacture, and distribution of products and services for the companion animal veterinary, livestock and poultry, water testing, and dairy markets.

Sotera Health Co

HEALTHCARE · DIAGNOSTICS & RESEARCH · USA

Sotera Health Company provides sterilization, laboratory testing, and advisory services to the medical device, pharmaceutical, and food industries in the Americas, Europe, and Asia. The company is headquartered in Broadview Heights, Ohio.

Want to dig deeper into these stocks?